Almirall commercialises Neurofarmagen, an innovative genetic test

• The test, to be used in psychiatry and neurology, analyses a DNA extract from a saliva sample 
• This permits personalised treatment  based on the patient's pharmacogenetic profile in psychiatric and neurological diseases such as depression, schizophrenia, bipolar disorder, epilepsy and Attention Deficit Hyperactivity Disorder (ADHD)
• Pharmacogenetics complements Almirall's R&D pipeline, which focuses on respiratory diseases, gastrointestinal disorders and dermatology

Barcelona, 8 February 2013.- Almiralli s now commercialising Neurofarmagen in Spain. This is a pharmacogenetic test to be used in psychiatry and neurology that aims to identify the most appropriate medication for each individual.  The launching of this product is a further commitment by Almirall to innovation through pharmacogenetics and personalised medicine.

This genetic test uses DNA from a saliva sample to create personalised treatment in psychiatric and neurological diseases such as depression, schizophrenia, bipolar disorder, epilepsy and ADHD.

The test has been developed by AB-Biotics, a company in which Almirall has  a stake. It helps when selecting from among various pharmacological alternatives, provides a guide to the best dosage for each patient and anticipates information about possible side effects.

Pharmacogenetics complements Almirall's R&D pipeline, which at present is focused on respiratory diseases, gastrointestinal disorders, dermatology and pain.  

Personalised medicine

Pharmacogenetics is the branch of genetics that studies how genetic variations or polymorphisms affect patient response to medicines.  As drug response may be conditioned up to95% by genetic factors, the use of pharmacogenetic tests when prescribing medicine enables the doctor to maximise therapeutic efficacy and minimise the risk of side effects through personalised medicine.

Almirall

Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing. Almirall focuses its research resources on respiratory, gastrointestinal, dermatology and pain. Almirall's medicines are currently present in over 70 countries while it has direct presence in Europe, México and Canada through 13 affiliates.

For further information, please visit our website at www.almirall.com

More information:                                                        Investor Relations contact

Ketchum                                                                       Almirall

Sonia San Segundo                                                     Jordi Molina

sonia.sansegundo@ketchum.com                                 jordi.molina@almirall.com

Tel.: 00 34 91 788 32 00                                               Tel.: 00 34 93 291 30 87